A model for identifying cytomegalovirus in patients with inflammatory bowel disease

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 1, 2015, Pages 131-137

  McCurdy, Jeffrey D ^a   Jones, Andrea ^a   Enders, Felicity T ^a   Killian, Jill M ^a   Loftus, Edward V ^a   Smyrk, Thomas C ^a   Bruining, David H ^a  

^a MAYO CLINIC   (United States)

Author keywords

CD; Comorbidity; Complication; UC

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB; IMMUNOLOGIC FACTOR;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; INTESTINE ULCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT IDENTIFICATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TREATMENT RESPONSE; ULCERATIVE COLITIS; AGED; COMPLICATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DECISION SUPPORT SYSTEM; EVALUATION STUDY; INFLAMMATORY BOWEL DISEASES; ISOLATION AND PURIFICATION; MIDDLE AGED; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84916909511     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.05.026     Document Type: Article

References (37)

1. Kishore J., Ghoshal U., Ghoshal U.C., et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. JMed Microbiol 2004, 53(Pt 11):1155-1160.
2. Goodman Z.D., Boitnott J.K., Yardley J.H. Perforation of the colon associated with cytomegalovirus infection. Dig Dis Sci 1979, 24:376-380.
3. Goodgame R.W., Genta R.M., Estrada R., et al. Frequency of positive tests for cytomegalovirus in AIDS patients: endoscopic lesions compared with normal mucosa. Am J Gastroenterol 1993, 88:338-343.
4. Cottone M., Pietrosi G., Martorana G., et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001, 96:773-775.
5. Wada Y., Matsui T., Matake H., et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum 2003, 46(Suppl):S59-S65.
6. Kuwabara A., Okamoto H., Suda T., et al. Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease. JGastroenterol 2007, 42:823-829.
7. Roblin X., Pillet S., Berthelot P., et al. Prevalence of cytomegalovirus infection in steroid-refractory Crohn's disease. Inflamm Bowel Dis 2012, 18:E1396-E1397.
8. McCurdy J.D., Loftus E.V.J., Tremaine W.J., et al. Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes. Inflamm Bowel Dis 2013, 19:2394-2399.
9. Domenech E., Vega R., Ojanguren I., et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 2008, 14:1373-1379.
10. Begos D.G., Rappaport R., Jain D. Cytomegalovirus infection masquerading as an ulcerative colitis flare-up: case report and review of the literature. Yale J Biol Med 1996, 69:323-328.
11. Papadakis K.A., Tung J.K., Binder S.W., et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001, 96:2137-2142.
12. Kambham N., Vij R., Cartwright C.A., et al. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004, 28:365-373.
13. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. JCrohn's Colitis 2009, 3:47-91.
14. Bitton A., Buie D., Enns R., et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012, 107:179-195.
15. Turner D., Travis S.P.L., Griffiths A.M., et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011, 106:574-588.
16. Matsuoka K., Iwao Y., Mori T., et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007, 102:331-337.
17. Kandiel A., Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006, 101:2857-2865.
18. Pillet S., Pozzetto B., Jarlot C., et al. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis 2012, 44:541-548.
19. Nguyen M., Bradford K., Zhang X., et al. Cytomegalovirus reactivation in ulcerative colitis patients. Ulcers 2011, 2011:1-7.
20. Garrido E., Carrera E., Manzano R., et al. Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease. World J Gastroenterol 2013, 19:17-25.
21. Lawlor G., Moss A.C. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?. Inflamm Bowel Dis 2010, 16:1620-1627.
22. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. NEngl J Med 1987, 317:1625-1629.
23. Harrell F. Regression coefficients and scoring rules. JClin Epidemiol 1996, 49:819.
24. Herfarth H.H., Long M.D., Rubinas T.C., et al. Evaluation of a non-invasive method to detect cytomegalovirus (CMV)-DNA in stool samples of patients with inflammatory bowel disease (IBD): a pilot study. Dig Dis Sci 2010, 55:1053-1058.
25. Nakase H., Yoshino T., Honzawa Y., et al. Low prevalence ofCMV infection in patients with Crohn's disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection. Dig Dis Sci 2010, 55:1498-1499.
26. Kim J.J., Simpson N., Klipfel N., et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 2010, 55:1059-1065.
27. Suzuki H., Kato J., Kuriyama M., et al. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol 2010, 16:1245-1251.
28. Criscuoli V., Rizzuto M.-R., Cottone M. Cytomegalovirus and inflammatory bowel disease: is there a link?. World J Gastroenterol 2006, 12:4813-4818.
29. Roblin X., Pillet S., Oussalah A., et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol 2011, 106:2001-2008.
30. Forbes B.A., Bonville C.A., Dock N.L. The effects of a promoter of cell differentiation and selected hormones on human cytomegalovirus infection using an invitro cell system. JInfect Dis 1990, 162:39-45.
31. Widmann T., Sester U., Gartner B.C., et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One 2008, 3:e3634.
32. Dimitroulia E., Spanakis N., Konstantinidou A.E., et al. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:879-884.
33. D'Ovidio V., Vernia P., Gentile G., et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. JClin Virol 2008, 43:180-183.
34. Lavagna A., Bergallo M., Daperno M., et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007, 13:896-902.
35. Davignon J.-L., Boyer J.-F., Jamard B., et al. Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments. Arthritis Res Ther 2010, 12:R142.
36. Adler S.P., Hempfling S.H., Starr S.E., et al. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 1998, 17:200-206.
37. Nakase H., Chiba T. TNF-alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. Inflamm Bowel Dis 2010, 16:550-551.